title: [Studies on the recurrent trophoblastic disease].
abstract: We studied the remission and the recurrent of trophoblastic disease treated in our clinic, during 1973 to 1980. 1) The remission and recurrent rates of 168 cases were 91.1% (153/168) and 5.2% (8/153) respectively. In these percentages, high risk was 65.9% (29/44) and 20.7% (6/29), low risk was 100% (124/124) and 1.6% (2/124), choriocarcinoma was 58.3% (21/36) and 28.6% (6/21), invasive mole was 100% (44/44) and 0, and undetermined was 100% (88/88) and 2.3% (2/88). 2) The interval to recurrence: 5 cases appeared under a year, 3 cases did over a year. And remission rate of recurrent case was (4/8), high risk was (2/6), and low risk was (2/2). 3) HCG-beta titers when U-hCG decreased under the LH levels was higher until 3 months in the recurrent case of high risk than that unrecurrent, while we did not recognize any differences after 3 months. Therefore criteria of remission in high risk would occurred on continuous LH levels of U-hCG for 3 months. 4) High risk has been treated by 3 courses of additional chemotherapy, but that when hCG-beta titer over 1.0ng/ml require more chemotherapy.
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000652:urine; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D007986:Luteinizing Hormone / Q000652:urine; D009364:Neoplasm Recurrence, Local; D011247:Pregnancy; D011379:Prognosis; D012306:Risk; D014328:Trophoblastic Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000556:secondary; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000453:epidemiology*
chemical_list: D006063:Chorionic Gonadotropin; D007986:Luteinizing Hormone